Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On February 10, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2025 that ended December 31, 2024.</li><li>Following the company's recent license and collaboration agreement with Sarepta Therapeutics, 2025 is set to be a catalyst-rich year.</li><li>The company is now financed through 2028 and potentially through multiple commercial launches by Arrowhead and/or its partners, the first of which could occur this year for plozasiran for the treatment of familial chylomicronemia syndrome (FCS), which has a PDUFA date of November 18, 2025.</li></ul>

On February 10, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2025 that ended December 31, 2024.Following the company's recent license and collaboration agreement with Sarepta Therapeutics, 2025 is set to be a catalyst-rich year.The company is now financed through 2028 and potentially through multiple commercial launches by Arrowhead and/or its partners, the first of which could occur this year for plozasiran for the treatment of familial chylomicronemia syndrome (FCS), which has a PDUFA date of November 18, 2025.

Arrowhead Pharmaceuticals Inc - On February 10